SCHEMBL18990374

SCHEMBL18990374

CCOC(=O)C(C(=O)OCC)c1nc2c(c(=O)n(Cc3cc4cc(Cl)ccc4[nH]3)c(=O)n2C)n1C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ ALDH1A1 P00352 6/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MTHFD2 P13995 1/20 0.41
▸ LMNA P02545 4/20 0.41
▸ GAA P10253 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ HIF1A Q16665 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18989779 0.92 USP2 (0.41) POLBTSHRALDH1A1HSD17B10MTHFD2
SCHEMBL24554953 0.89 POLB (0.40) POLBTSHRALDH1A1MTHFD2LMNA
SCHEMBL18990096 0.89 LMNA (0.44) POLBTSHRALDH1A1HSD17B10MTHFD2
SCHEMBL18989887 0.84 TSHR (0.50) POLBTSHRALDH1A1HSD17B10MTHFD2
SCHEMBL19013916 0.81 LMNA (0.44) POLBTSHRALDH1A1HSD17B10MTHFD2
SCHEMBL19013524 0.81 MAPT (0.44) POLBALDH1A1MTHFD2LMNAHPGD
SCHEMBL18990258 0.80 LMNA (0.45) POLBALDH1A1MTHFD2LMNAGAA
SCHEMBL19013523 0.79 POLB (0.44) POLBTSHRALDH1A1MTHFD2LMNA
SCHEMBL18989728 0.78 TP53 (0.45) POLBALDH1A1MTHFD2LMNAGAA
SCHEMBL19013525 0.78 POLB (0.43) POLBTSHRALDH1A1MTHFD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2018-12-27 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 POLB 1467/4885TSHR 4484/4885ALDH1A1 260/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 POLB 1467/4885TSHR 4484/4885ALDH1A1 260/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 POLB 1467/4885TSHR 4484/4885ALDH1A1 260/4885
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 POLB 1467/4885TSHR 4484/4885ALDH1A1 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback